NCT03424928View on ClinicalTrials.gov

A Pilot Bioequivalence Study of Pomalidomide

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 19, 2018

Primary Completion Date

January 29, 2018

Study Completion Date

February 6, 2018

Conditions
Bioequivalence
Interventions
DRUG

Pomalidomide 4 MG Oral Capsule

per os,capsule,4mg,1 capsule per period

DRUG

Pomalidomide 4 MG Oral Capsule-Pomalyst

per os,capsule,4mg,1 capsule per period

Trial Locations (1)

030001

The second hospital of shanxi medical university, Taiyuan

Sponsors
All Listed Sponsors
collaborator

Second Hospital of Shanxi Medical University

OTHER

lead

Jiangsu Simcere Pharmaceutical Co., Ltd.

INDUSTRY

NCT03424928 - A Pilot Bioequivalence Study of Pomalidomide | Biotech Hunter | Biotech Hunter